Science
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 – EurekAlert
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab…
What The Study Did: This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab vs placebo on change in day 11 severe acute respiratory syndrome coronavirus 2 viral load in patients with mild to moderate COVID-19.
Authors: Daniel M. Skovronsky, M.D., Ph.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at…
-
General22 hours agoHundreds gather in Gin Gin at vigil for allegedly murdered teen Pheobe Bishop
-
Noosa News23 hours agoDaly Cherry-Evans set to be dropped as Maroons captain
-
Noosa News22 hours agoThe Story Bridge should serve as a warning – and an opportunity
-
General8 hours agoHeroic surfing priest rescues father and son from rip at Cable Beach